New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
11:52 EDTPSTIPluristem lack of disclosure on patient death in legal gray area, Bloomberg says
Pluristem Therapeutics' (PSTI) stock soared and at least two top executives profited in spite of the fact that a patient reportedly died months after using its experimental stem cell treatment, according to Bloomberg. The company has yet to make an announcement of the girl’s death, which may put it in a legal gray area in regards to U.S. securities laws, the report noted. Reference Link
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
09:52 EDTPSTIPluristem raises $17M in a registered direct offering
Subscribe for More Information
June 24, 2015
05:30 EDTPSTIPluristem granted Australian patent for 3D cell expansion technology
Pluristem Therapeutics announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". Patent #2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions. These include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases. The patent term will extend until 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use